摘要
为保障新型冠状病毒肺炎(COVID-19)突发公共卫生事件中药品供应稳定,2020年4月欧盟发布了"COVID-19持续期间的最优和合理药品供应以避免药品短缺的指导原则"。该指导原则提供了公共卫生事件期间,欧盟成员国维持药品供应稳定应遵循的工作建议;并针对COVID-19治疗用药品和因疫情影响而具有短缺风险的药品,提出维持药品供应、流通和使用的最优措施。介绍该指导原则的主要内容,以期为完善中国公共卫生体系建设提供参考。
To ensure the stable supply of medicines in European Union(EU) during the coronavirus disease 2019(COVID-19)public health emergency, EU has published Guidelines on the optimal and rational supply of medicines to avoid shortages during the COVID-19 outbreak in April 2020. This guideline aimed to prompt EU Member States with concrete actions for the stable supply of medicines during the public health emergency. The guideline focused on the rational supply, allocation and use of medicines to treat COVID-19 patients but also covered any medicine at risk of shortage due to the pandemic. The main content of this guideline is introduced, which is expected to provide reference for perfecting the public health system of China.
作者
王胜鹏
朱炯
王翀
张弛
WANG Shengpeng;ZHU Jiong;WANG Chong;ZHANG Chi(National Institutes for Food and Drug Control,Beijing 100050,China)
出处
《药物评价研究》
CAS
2020年第11期2158-2162,共5页
Drug Evaluation Research